Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration [Phase 3]

View source ↗

Summary

This clinical trial update indicates that Ocular Therapeutix is evaluating intravitreal axitinib implants (OTX-TKI) for neovascular age-related macular degenera…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• OTX-TKI Axitinib Implant (axitinib)

Snippet

Sponsor: Ocular Therapeutix, Inc. | Conditions: Neovascular Age-Related Macular Degeneration | Phase 3 | Status: ACTIVE_NOT_RECRUITING